Page last updated: 2024-11-08

homoegonol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

homoegonol: has anti-asthmatic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID176929
CHEMBL ID3634694
SCHEMBL ID15258226
MeSH IDM000605370

Synonyms (15)

Synonym
3-[2-(3,4-dimethoxyphenyl)-7-methoxy-benzofuran-5-yl]propan-1-ol
5-(3''-hydroxypropyl)-7-methoxy-2-(3',4'-dimethoxyphenyl)benzofuran
homoegonol
3-[2-(3,4-dimethoxyphenyl)-7-methoxy-1-benzofuran-5-yl]propan-1-ol
FT-0669223
17375-66-5
2-(3,4-dimethoxyphenyl)-5-(3-hydroxypropyl)-7-methoxybenzofuran
SCHEMBL15258226
3-[2-(3,4-dimethoxyphenyl)-7-methoxy-1-benzofuran-5-yl]-1-propanol #
5-benzofuranpropanol, 2-(3,4-dimethoxyphenyl)-7-methoxy-
PFOARMALXZGCHY-UHFFFAOYSA-N
CHEMBL3634694
DTXSID50169651
3-(2-(3,4-dimethoxyphenyl)-7-methoxybenzofuran-5-yl)propan-1-ol
3-[2-(3,4-dimethoxyphenyl)-7-methoxybenzofuran-5-yl]-1-propanol

Research Excerpts

Overview

Homoegonol is a lignan derived from styraxlignolide A. It was isolated from Styrax japonica, a medicinal plant widely used for treatment of inflammatory diseases.

ExcerptReferenceRelevance
"Homoegonol is a lignan derived from styraxlignolide A, which was isolated from Styrax japonica, a medicinal plant widely used for treatment of inflammatory diseases in Korea. "( Homoegonol attenuates the asthmatic responses induced by ovalbumin challenge.
Ahn, KS; Chin, YW; Jeon, CM; Kwon, OK; Lee, K; Oh, SR; Shin, IS; Shin, NR, 2014
)
3.29

Treatment

ExcerptReferenceRelevance
"The homoegonol-treated mice exhibited reduced inflammatory cell counts and Th2 cytokines in BALF, AHR, and IgE in the serum compared with the OVA-sensitized/challenged mice."( Homoegonol attenuates the asthmatic responses induced by ovalbumin challenge.
Ahn, KS; Chin, YW; Jeon, CM; Kwon, OK; Lee, K; Oh, SR; Shin, IS; Shin, NR, 2014
)
2.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1498471Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Access to new highly potent antileukemia, antiviral and antimalarial agents via hybridization of natural products (homo)egonol, thymoquinone and artemisinin.
AID1498472Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes after 72 hrs by SYBR green dye fluorescence assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Access to new highly potent antileukemia, antiviral and antimalarial agents via hybridization of natural products (homo)egonol, thymoquinone and artemisinin.
AID1256625Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production at 3 to 30 ug/ml after 24 hrs by Griess reaction2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Inhibitory effects of compounds from Styrax obassia on NO production.
AID1256626Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production at 30 ug/ml after 24 hrs by Griess reaction2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Inhibitory effects of compounds from Styrax obassia on NO production.
AID1498470Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Access to new highly potent antileukemia, antiviral and antimalarial agents via hybridization of natural products (homo)egonol, thymoquinone and artemisinin.
AID1498473Antiviral activity against GFP-fused Human cytomegalovirus AD169 infected in primary HFF2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Access to new highly potent antileukemia, antiviral and antimalarial agents via hybridization of natural products (homo)egonol, thymoquinone and artemisinin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]